Cullen’s article looks at how AI is likely to accelerate the process of developing drugs and identifying patients who can benefit from them. It outlines patentability challenges for policy makers as well as increased risks for holders of non-patented IP – including trade secrets. A fourth consideration evolves around data, its increased value, monetisation issues and related concerns for data owners.
Read the full article on Pharma Times Magazine here
Authored by Cullen G Taylor